Scott Habig Biography and Net Worth

Chief Commercial Officer of Aurinia Pharmaceuticals


Scott Habig joins Aurinia as Chief Commercial Officer with more than 20 years of global and U.S. sales and marketing experience, and relevant expertise in rheumatology and lupus markets.

A transformational leader and collaborator, Scott has an accomplished history of engaging and inspiring sales forces, creating patient-centric environments, and blending strategic leadership and forecasting abilities to exceed expectations and business goals. Over the past ten years, Scott has held numerous leadership roles at UCB, Inc. and most recently was Head of Global SLE, maintaining full responsibility for pre-launch and commercial launch activities of a novel CD40 ligand currently in Phase III of clinical development for Systemic Lupus Erythematosus (SLE). His previous roles include Vice President, Sales at Human Genome Sciences, where he led the development and execution of organizational capabilities and infrastructure to support the company’s first sales team and led organizational and operational initiatives to guide the first major lupus drug launch in more than 50 years. Prior to this role, Scott spent nine years at Centocor, Inc. where he led the development and execution of sales and marketing strategies for one of the first biologic therapies approved for multiple autoimmune disorders. Under Scott’s sales and marketing leadership at Centocor, the company transformed a multimillion-dollar pipeline into a multibillion-dollar product.

What is Scott Michael Habig's net worth?

The estimated net worth of Scott Michael Habig is at least $3.67 million as of August 6th, 2024. Mr. Habig owns 456,338 shares of Aurinia Pharmaceuticals stock worth more than $3,668,958 as of April 1st. This net worth approximation does not reflect any other assets that Mr. Habig may own. Learn More about Scott Michael Habig's net worth.

How old is Scott Michael Habig?

Mr. Habig is currently 64 years old. There are 5 older executives and no younger executives at Aurinia Pharmaceuticals. Learn More on Scott Michael Habig's age.

How do I contact Scott Michael Habig?

The corporate mailing address for Mr. Habig and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at ir@auriniapharma.com. Learn More on Scott Michael Habig's contact information.

Has Scott Michael Habig been buying or selling shares of Aurinia Pharmaceuticals?

Scott Michael Habig has not been actively trading shares of Aurinia Pharmaceuticals over the course of the past ninety days. Most recently, Scott Michael Habig sold 18,249 shares of the business's stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a transaction totalling $96,902.19. Following the completion of the sale, the insider now directly owns 456,338 shares of the company's stock, valued at $2,423,154.78. Learn More on Scott Michael Habig's trading history.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 366,704 shares worth more than $2,888,411.85. The most recent insider tranaction occured on March, 7th when insider Greg Keenan sold 8,305 shares worth more than $68,350.15. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.

Information on this page was last updated on 3/7/2025.

Scott Michael Habig Insider Trading History at Aurinia Pharmaceuticals

See Full Table

Scott Michael Habig Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Scott Michael Habig's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $8.04
Low: $7.93
High: $8.23

50 Day Range

MA: $8.09
Low: $7.55
High: $8.67

2 Week Range

Now: $8.04
Low: $4.71
High: $10.67

Volume

1,474,687 shs

Average Volume

1,342,884 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26